menu

Immunotherapy: Changing Patient Outcomes in SCLC

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Immunotherapy: Changing Patient Outcomes in SCLC

close
Immunotherapy: Changing Patient Outcomes in SCLC
Restart
Resume
Choose a format
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Please note:This activity is no longer available for continuing education credit.

    Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with a poor prognosis. The recent addition of immunotherapy to the treatment landscape has changed the standard of care for ES-SCLC. In this interactive activity an expert will guide you through the latest evidence on checkpoint inhibitors for the management of ES-SCLC and offer expert insight into effectively and safely incorporating immunotherapy into your practice to improve patient outcomes.

  • Target Audience

    The intended audience for this activity is oncologists, as well as PAs and NPs, who manage patients with small cell lung cancer.

  • Learning Objectives

    Upon successful completion of this activity, participants should be better able to:

    1. Describe the mechanism of action of immune checkpoint inhibitors in SCLC and how this impacts their efficacy in managing SCLC
    2. Utilize an evidence-based approach to managing SCLC with current and emerging immunotherapies
    3. Proactively manage potential side effects of immunotherapies
    4. Employ a strong patient-provider collaborative approach, including shared decision making, to actively educate and engage patients with SCLC in their care
  • Faculty

    Leora Horn, MD, MSc
    AssociateProfessor, Medicine 
    Assistant Director, Educator Development Program
    Clinical Director, Thoracic Oncology Program  
    Vanderbilt University Medical Center
    Nashville, TN

  • Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    PHYSICIAN CONTINUING MEDICAL EDUCATION
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

  • Commercial Support

    This activity is supported by an educational grant from Genentech.

  • Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    • Leora Horn, MD, MSc, has affiliations with AstraZeneca, Bristol-Myers Squibb, EMD Serono, Genentech, Incyte, Merck, Tesaro, Xcovery (Consulting Fees); Boehringer Ingelheim, Bristol-Myers Squibb, Xcovery (Contracted Research). 

    Planners and Managers
    The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose. 

    CME Questions?
    If you would like to contact Postgraduate Institute for Medicine, please e-mail information@pimed.com.

    DISCLOSURE OF UNLABELED USE
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

  • How to Participate in this Activity and Obtain CME Credit

    By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the activity evaluation.

    Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please e-mail information@pimed.com.

  • Publication Dates

    Release Date:

    Expiration Date: This activity is no longer available for continuing education credit. 

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Please note:This activity is no longer available for continuing education credit.

    Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with a poor prognosis. The recent addition of immunotherapy to the treatment landscape has changed the standard of care for ES-SCLC. In this interactive activity an expert will guide you through the latest evidence on checkpoint inhibitors for the management of ES-SCLC and offer expert insight into effectively and safely incorporating immunotherapy into your practice to improve patient outcomes.

  • Target Audience

    The intended audience for this activity is oncologists, as well as PAs and NPs, who manage patients with small cell lung cancer.

  • Learning Objectives

    Upon successful completion of this activity, participants should be better able to:

    1. Describe the mechanism of action of immune checkpoint inhibitors in SCLC and how this impacts their efficacy in managing SCLC
    2. Utilize an evidence-based approach to managing SCLC with current and emerging immunotherapies
    3. Proactively manage potential side effects of immunotherapies
    4. Employ a strong patient-provider collaborative approach, including shared decision making, to actively educate and engage patients with SCLC in their care
  • Faculty

    Leora Horn, MD, MSc
    AssociateProfessor, Medicine 
    Assistant Director, Educator Development Program
    Clinical Director, Thoracic Oncology Program  
    Vanderbilt University Medical Center
    Nashville, TN

  • Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    PHYSICIAN CONTINUING MEDICAL EDUCATION
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

  • Commercial Support

    This activity is supported by an educational grant from Genentech.

  • Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    • Leora Horn, MD, MSc, has affiliations with AstraZeneca, Bristol-Myers Squibb, EMD Serono, Genentech, Incyte, Merck, Tesaro, Xcovery (Consulting Fees); Boehringer Ingelheim, Bristol-Myers Squibb, Xcovery (Contracted Research). 

    Planners and Managers
    The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose. 

    CME Questions?
    If you would like to contact Postgraduate Institute for Medicine, please e-mail information@pimed.com.

    DISCLOSURE OF UNLABELED USE
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

  • How to Participate in this Activity and Obtain CME Credit

    By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the activity evaluation.

    Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please e-mail information@pimed.com.

  • Publication Dates

    Release Date:

    Expiration Date: This activity is no longer available for continuing education credit. 

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 7/14/20